INEX Innovate
INEX Innovate is a Singapore-based molecular diagnostics company that develops and commercialises proprietary tests and laboratory services for women's and fetal health across Asia, anchored by OvaCis® (intraoperative ovarian cyst discrimination), LEXI® (fetal cell isolation NIPD), and cancer liquid biopsies epiDx®, XENA®, and epiHERA®.
- Company typePrivate
- Founded2006
- HeadquartersSingapore, Singapore
- Headcount101–250
- GTM typeB2B
- OfferingServices
What INEX Innovate does
INEX Innovate Pte Ltd is a Singapore-headquartered molecular diagnostics company that develops and commercialises proprietary tests and laboratory services for women's and fetal health across Asia. The company's product portfolio is anchored in five core women's-health diagnostics: OvaCis®, an immunochromatographic point-of-care device that discriminates benign from malignant epithelial ovarian cysts in 15 minutes via haptoglobin detection in cyst fluid (received HSA Singapore approval in March 2024 and CE-IVD certification in May 2022); epiDx®, a methylation-based liquid biopsy for breast cancer; epiHERA®, a PCR test using hypermethylated CDO1/CELF4 markers for early endometrial cancer detection; XENA®, a blood-based liquid biopsy for early ovarian cancer detection; and LEXI®, a patented methodology for isolating fetal cells from maternal blood for non-invasive prenatal diagnosis with potential coverage of over 7,000 genetic conditions. Underlying platforms span Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), bisulfite conversion methylation analysis, and proprietary fetal cell isolation, supported by 47+ patents, 9 trademarks, and exclusive NGS and NIPT licences from global medical centres.
The wholly-owned subsidiary iGene Laboratory Pte Ltd (established 2014, CAP-accredited and Singapore MOH-licensed) provides clinical testing services including COVID-19 RT-PCR and serology, preeclampsia screening, whole exome sequencing (FetalExome), monkeypox PCR, and non-invasive prenatal tests including Rhene™ for fetal RhD status. INEX generates revenue through three streams: hardware sales of diagnostic kits and point-of-care devices to hospitals and surgical centres (e.g. OvaCis®, CORO®); professional services revenue from iGene's laboratory testing for clinicians and patients across Southeast Asia; and licensing and royalty revenue from technology transfer to regional partners. Distribution combines direct enterprise sales with channel partnerships, notably Biomed Global as exclusive distributor for OvaCis® across Indonesia, Malaysia, Philippines, Singapore, and Thailand.
Strategic positioning reflects an Asia-first women's-health niche: institutional backing from Enterprise Singapore, Genting Berhad, and PwC; leadership from clinician-scientists including A/Prof. Mahesh Choolani (co-founder, NUH) and Dr. Chia Pin Chang (former A*STAR Principal Investigator); and a 2023 board refresh chaired by former Enterprise Singapore Deputy CEO Ted Tan. The June 2023 acquisition of Yourgene Health (Taiwan) for up to S$5.4 million added a Taiwan genomics footprint plus bioinformatics capability, while prior partnerships with Eli Lilly (genotyping), Inalways Corporation, the Chinese University of Hong Kong, and the University of Malaya Medical Centre validate pharma and academic demand for the platform.
INEX Innovate firmographics
Firmographics- Name
- INEX Innovate
- Legal name
- INEX Innovate Pte Ltd
- Website
- https://inex.sg
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- INEX Innovate is a Singapore-based molecular diagnostics company that develops and commercialises proprietary tests and laboratory services for women's and fetal health across Asia, anchored by OvaCis® (intraoperative ovarian cyst discrimination), LEXI® (fetal cell isolation NIPD), and cancer liquid biopsies epiDx®, XENA®, and epiHERA®.
- Ownership category
- akta.pro rank
INEX Innovate industry classification
Industry- Product category
- Women's Health Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Proteomics & Biomarker Analytical Testing (HLAGADAG), IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
Keywords
Where INEX Innovate is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
INEX Innovate business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Kits (Point-of-Care Devices): INEX sells proprietary diagnostic test kits and point-of-care medical devices such as OvaCis® and CORO® Real-Time RT-PCR SARS-CoV-2 kit, generating one-time or recurring product revenue from healthcare facilities.
- Laboratory Testing Services: iGene Laboratory, the wholly-owned subsidiary, offers clinical laboratory testing services including NGS, PCR, COVID-19 testing, preeclampsia screening, whole exome sequencing, Non-Invasive Prenatal Test (NIPT), and fetal RhD status testing to medical professionals and patients across Southeast Asia.
- Licensing & Technology Transfer: INEX licenses its technology, patents, trademarks, and proprietary know-how to partners in new markets through technology transfer models, generating licensing and royalty revenue.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
INEX Innovate product offering
Product offeringCore offering
INEX Innovate develops and commercialises proprietary molecular diagnostic test kits and point-of-care medical devices focused on women's and fetal health, including intraoperative ovarian cancer discrimination (OvaCis®), methylation-based liquid biopsies for breast/endometrial/ovarian cancer (epiDx®, epiHERA®, XENA®), and non-invasive prenatal diagnostics (LEXI®). Through its wholly-owned subsidiary iGene Laboratory, it also delivers clinical laboratory testing services using NGS and PCR platforms.
Product overview
INEX Innovate is a molecular diagnostics company offering a portfolio of diagnostic products for women's and fetal health. The portfolio includes OvaCis® (intraoperative point-of-care device for ovarian cancer discrimination in 15 minutes), epiDx® (blood-based liquid biopsy for breast cancer), epiHERA® (minimally invasive endometrial cancer detection), XENA® (early detection liquid biopsy for ovarian cancer), LEXI® (non-invasive prenatal diagnostic isolating fetal cells), and CORO® (RT-PCR SARS-CoV-2 kit). The wholly-owned subsidiary iGene Laboratory provides clinical testing services including COVID-19 testing, Preeclampsia screening, Whole Exome Sequencing (FetalExome), Monkeypox testing, and Non-Invasive Prenatal Tests such as Rhene™ for fetal RhD status. Products operate on core technology platforms including RT-PCR, immunochromatographic assays, bisulfite conversion with methylation analysis, and Next Generation Sequencing (NGS).
Differentiator
Problem solved
Functional benefit
Brands
- iGene Laboratory: Wholly owned subsidiary clinical laboratory offering tests based on Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) technologies.
Products and services
- OvaCis® Globally patented intraoperative point-of-care medical device that discriminates benign from malignant epithelial ovarian cancer in 15 minutes using haptoglobin biomarker detection in ovarian cyst fluid. Sold to hospitals, surgical centers, and gynecological surgeons.
- epiDx®
Quantifiable outcome
- OvaCis® discriminates benign from malignant ovarian cysts in 15 minutes during surgery
- +2 more outcomes
Companies that use INEX Innovate
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
INEX Innovate technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
INEX Innovate partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Yourgene Health (Taiwan) Co., LtdcoreINEX Innovate entered an agreement to acquire the Taiwan genomics business of UK-listed Yourgene Health PLC (LON: YGEN) for up to S$5.4 million, completed in June 2023. The acquisition strengthens INEX's capabilities in fetal health, oncology R&D, and bioinformatics. Yourgene Health (Taiwan) Co., Ltd was a Taiwan-based genomics firm.
- Biomed GlobalcoreINEX Innovate appointed Biomed Global as the distributor for the launch of OvaCis® — the company's test for ovarian cancer — in Indonesia, Malaysia, Philippines, Singapore, and Thailand.
- Hegenberger Medical LimitedminorINEX Innovate was appointed by UK-based Hegenberger Medical Limited as a strategic Enterprise Partner for the Hegenberger Retractor in Singapore.
- The Chinese University of Hong Kong (CUHK)minorINEX Innovate announced funding for new research with CUHK, supporting molecular diagnostics development and clinical research collaboration.
- Eli Lilly and CompanycoreINEX Innovate announced a personalised medicine project with Eli Lilly and Company's research unit, involving Lilly genotyping analysis. This collaboration supports INEX's research and clinical programmes.
- University of Malaya Medical Centre (UMMC)minorINEX Innovate inked an agreement with UMMC to supply RT-PCR test kits, supporting Malaysia's COVID-19 testing capacity.
- Inalways CorporationminorINEX Innovate entered into a partnership with Taiwan-listed biotechnology group Inalways Corporation to support molecular diagnostics expansion and market access.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
INEX Innovate competitors and assessment
Company assessmentEmerging players
- Guardant Health, Inc. Guardant Health is a US liquid biopsy company focused on oncology. It overlaps with INEX's epiDx and XENA blood-based cancer detection products at the technology and customer level, but is at a much later commercialisation stage in oncology.
- Veracyte, Inc. Veracyte is a molecular diagnostics company specialising in genomic tests for cancer. It is comparable to INEX's epiDx, XENA, and epiHERA products in the use of methylation/epigenetic and RNA-based assays to stratify cancer patients, particularly in the early-detection niche.
Direct peers
- BGI Genomics Co., Ltd. BGI Genomics is a major Asia-based molecular diagnostics and sequencing company with NIPT, oncology, and reproductive health offerings. It is the most direct large-scale peer to INEX in the Asia-Pacific molecular diagnostics market, with comparable products and regional reach.
- Natera, Inc. Natera is a US-listed molecular diagnostics company with leading franchises in non-invasive prenatal testing (NIPT) and oncology liquid biopsy — directly comparable to INEX's NIPT (Rhene, FetalExome) and cancer (epiDx, XENA) diagnostics, and competing for the same hospital and lab customers globally.
- Yourgene Health plc: UK-listed NIPT and reproductive health genomics company whose Taiwan subsidiary was acquired by INEX in 2023. Yourgene is a direct peer in NIPT and fetal health, with overlapping reproductive diagnostics technology and go-to-market in Asia-Pacific.
- Myriad Genetics, Inc. Myriad Genetics is a molecular diagnostics company historically focused on hereditary cancer and women's health testing (e.g., BRACAnalysis, Foresight carrier screen). It is a direct peer in genetic and epigenetic cancer risk and prenatal diagnostics.
- NeoGenomics, Inc. NeoGenomics is a US cancer-focused clinical laboratory and molecular diagnostics provider. It is directly comparable to INEX's iGene Laboratory in providing oncology and women's health genetic testing services to hospitals and physicians.
Broad incumbents
- Sysmex Corporation: Sysmex is a Japanese IVD leader with strong Asia-Pacific presence in haematology, clinical chemistry, and molecular diagnostics. It is a broad incumbent whose regional scale and hospital channel overlap with INEX's target customer base across Southeast Asia.
- Hologic, Inc. Hologic is a global women's health diagnostics and surgical company with established franchises in cytology, NIPT, and breast cancer screening (e.g., ThinPrep, Panther system). It is a broad incumbent whose scale and hospital relationships set the competitive benchmark INEX must beat in women's diagnostics.
- Roche Diagnostics: Roche is the largest in-vitro diagnostics company globally, with deep portfolios in prenatal screening, oncology, and PCR platforms. It competes with INEX across molecular diagnostics workflows, lab services, and oncology biomarkers, but as part of a much broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
INEX Innovate social profiles
Digital presenceINEX Innovate compliance and trust
Trust signalCompliance3 records
INEX Innovate financial estimates
Financial estimateRevenue estimate
Valuation estimate
INEX Innovate leadership team
Management profileNumber of profiles
Profiles14 records
INEX Innovate subsidiaries and ownership
Company hierarchySubsidiaries2 records
INEX Innovate funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
INEX Innovate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about INEX Innovate
What does INEX Innovate do?
INEX Innovate develops and commercialises proprietary molecular diagnostic test kits and point-of-care medical devices focused on women's and fetal health, including intraoperative ovarian cancer discrimination (OvaCis®), methylation-based liquid biopsies for breast/endometrial/ovarian cancer (epiDx®, epiHERA®, XENA®), and non-invasive prenatal diagnostics (LEXI®). Through its wholly-owned subsidiary iGene Laboratory, it also delivers clinical laboratory testing services using NGS and PCR platforms.
Is INEX Innovate a public or private company?
INEX Innovate is a private company. It is classified as venture growth investor backed and is currently operating.
When was INEX Innovate founded?
INEX Innovate was founded in 2006. It employs 101 to 250 people.
Where is INEX Innovate based?
INEX Innovate is headquartered in Singapore, Singapore, in the Asia region.
How does INEX Innovate make money?
Three revenue lines are on record. Diagnostic Test Kits (Point-of-Care Devices) is the primary driver. The others are laboratory Testing Services and licensing & Technology Transfer.
Who are INEX Innovate's main competitors?
Emerging players on record are Guardant Health, Inc. and Veracyte, Inc.. Direct peers are BGI Genomics Co., Ltd., Natera, Inc., Yourgene Health plc, Myriad Genetics, Inc. and NeoGenomics, Inc.. Broad incumbents are Sysmex Corporation, Hologic, Inc. and Roche Diagnostics.
Does INEX Innovate have an API?
No public API is recorded for INEX Innovate.
What industry is INEX Innovate in?
INEX Innovate's product category is Women's Health Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 325413 and its SIC code is 2835.